Analysis of the efficacy of subretinal injection and intravitreal injection of conbercept in the treatment of polypoidal choroidal vasculopathy_Chinese Journal of Ocular Fundus Diseases

Authors：

Liu Teng , Yu Xiao , Wu Xiaojian , Zou Yuling , Liu Kangcheng , Zou Hua , Wu Wei , Xu Chenghao ,  You Zhipeng

Affiliated Eye Hospital of Nanchang University, Eye Hospital of Jiangxi Province, Nanchang 330006, China;

Corresponding?author：

You Zhipeng, Email: yzp@sina.com

Keywords：

Polypoid choroidal vasculopathy; Subretinal injection; Intravitreal injection; Conbercept

DOI：

10.3760/cma.j.cn511434-20240112-00023

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To observe the clinical effect of subretinal injection and intravitreal injection of conbercept in the treatment of polypoid choroidal vasculopathy (PCV). Methods A prospective, randomized double-blind controlled study. From June 2022 to January 2023, 35 patients of 35 eyes with PCV diagnosed at Affiliated Eye Hospital of Nanchang University were included in the study. All patients were first-time recipients of treatment. Best corrected visual acuity (BCVA), optical coherence tomography (OCT), and indocyanine green angiography (ICGA) were performed in all affected eyes. BCVA was performed using an international standard visual acuity chart and converted to logarithmic minimum resolved angle (logMAR) visual acuity for statistical purposes. Enhanced depth imaging with OCT instrument was used to measure the macular retinal thickness (MRT), subfoveal choroidal thickness (SFCT), and pigment epithelium detachment (PED) height. Randomized numerical table method was used to divide the patients into subretinal injection group (group A) and vitreous cavity injection group (Group B), 18 cases with 18 eyes and 17 cases with 17 eyes, respectively. Comparison of age (t=0.090), disease duration (t=?0.370), logMAR BCVA (t=?0.190), MRT (t=0.860), SFCT (t=0.247), and PED height (t=?0.520) between the two groups showed no statistically significant difference (P＞0.05). The eyes of group A were given one subretinal injection of 10 mg/ml conbercept 0.05 ml (containing conbercept 0.5 mg), and subsequently administered on demand (PRN); eyes in group B were given intravitreal injection of 10 mg/ml conbercept 0.05 ml (containing conbercept 0.5 mg). The treatment regimen was 3+PRN. Lesions were categorized into active and quiescent according to the results of post-treatment OCT and BCVA. Active lesions were treated with intravitreal injection of conbercept at the same dose as before; stationary lesions were followed up for observation. BCVA and OCT were performed at 1, 2, 3, 6 and 9 months after treatment; ICGA was performed at 3, 6 and 9 months. BCVA, MRT, SFCT, and PED height changes before and after treatment were compared and observed in the affected eyes of the two groups. Independent sample t-test was used to compare between the two groups. Results With the prolongation of time after treatment, the BCVA of the affected eyes in groups A and B gradually increased, and the MRT, SFCT, and PED height gradually decreased. Compared with group B, at 2, 3, 6, and 9 months after treatment, the BCVA of group A was significantly improved, and the difference was statistically significant (t=?2.215, ?2.820, ?2.559, ?4.051; P＜0.05); at 1, 2, 3, 6, and 9 months after treatment, the MRT of the affected eyes in group A (t=?2.439, ?3.091, ?3.099, ?3.665, ?5.494), SFCT (t=?3.370, ?3.058, ?3.268, ?4.220, ?4.121), and PED height (t=?3.460, ?4.678, ?4.956, ?5.368, ?6.396) were significantly reduced, and the differences were statistically significant (P＜0.05). No complications such as intraocular inflammation, high intraocular pressure, or vitreous hemorrhage occurred in any of the affected eyes during or after treatment. Conclusion Compared with the intravitreal injection of conbercept, the subretinal injection of conbercept can more effectively reduce the height of MRT, SFCT, PED height, and improve the visual acuity of the affected eyes with PCV.

Citation： Liu Teng, Yu Xiao, Wu Xiaojian, Zou Yuling, Liu Kangcheng, Zou Hua, Wu Wei, Xu Chenghao, You Zhipeng. Analysis of the efficacy of subretinal injection and intravitreal injection of conbercept in the treatment of polypoidal choroidal vasculopathy. Chinese Journal of Ocular Fundus Diseases, 2024, 40(6): 421-428. doi: 10.3760/cma.j.cn511434-20240112-00023 Copy

1.	Cher YX, Zhang YQ, Chen CZ, et al. Chinese guideline on the management of polypoidal choroidal vasculopathy (2022)[J]. Chin Med Sci J, 2023, 38(2): 77-93. DOI: 10.24920/004213.
2.	Cheung C, Lai T, Teo K, et al. Polypoidal choroidal vasculopathy: consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup[J]. Ophthalmology, 2021, 128(3): 443-452. DOI: 10.1016/j.ophtha.2020.08.006.
3.	任晴, 崔蕾, 高磊. 息肉樣脈絡膜血管病變的臨床特征與手術治療進展[J]. 國際眼科雜志, 2018, 18(10): 1810-1814. DOI: 10.3980/j.issn.1672-5123.2018.10.12.Ren Q, Cui L, Gao L. Clinical features and progress of surgical therapy for polypoidal choroidal vasculopathy[J]. Int Eye Sci, 2018, 18(10): 1810-1814. DOI: 10.3980/j.issn.1672-5123.2018.10.12.
4.	Chen LJ, Cheng CK, Yeung L, et al. Management of polypoidal choroidal vasculopathy: experts consensus in Taiwan[J]. J Formos Med Assoc, 2020, 119(2): 569-576. DOI: 10.1016/j.jfma.2019.04.012.
5.	Sen P, Manayath G, Shroff D, et al. Polypoidal choroidal vasculopathy: an update on diagnosis and treatment[J]. Clin Ophthalmol, 2023, 17: 53-70. DOI: 10.2147/OPTH.S385827.
6.	朱哲. 影響息肉狀脈絡膜血管病變(PCV)患者發生黃斑區視網膜下纖維化瘢痕的相關因素分析[D]. 長春: 吉林大學, 2021.Zhu Z. Analysis of related factors affecting subretinal fibrosis scar in macular area in patients with polypoid choroidal vasculopathy (PCV)[D]. Changchun: Jilin University, 2021.
7.	梁燕華, 宋艷萍, 丁琴, 等. 單純光動力療法與玻璃體腔注射雷珠單抗以及兩者聯合治療息肉樣脈絡膜血管病變療效比較[J]. 中華眼底病雜志, 2016, 32(1): 31-35. DOI: 10.3760/cmaj. issn. 1005-1015.2016. 01.008.Liang YH, Song YP, Ding Q, et al. Efficacy of photodynamic therapy and intravitreal injection of ranibizumab in patients with polypoidal choroidal vasculopathy[J]. Chin J Ocul Fundus Dis, 2016, 32(1): 31-35. DOI: 10.3760/cmaj.issn.1005-1015.2016.01.008.
8.	Irigoyen C, Amenabar Alonso A, Sanchez-Molina J, et al. Subretinal injection techniques for retinal disease: a review[J]. Journal of Clinical Medicine, 2022, 11(16): 4717. DOI: 10.3390/jcm11164717.
9.	Del AE, Rimpela AK, Heikkinen E, et al. Pharmacokinetic aspects of retinal drug delivery[J]. Prog Retin Eye Res, 2017, 57: 134-185. DOI: 10.1016/j.preteyeres.2016.12.001.
10.	Simunovic MP, Xue K, Jolly JK, et al. Structural and functional recovery following limited iatrogenic macular detachment for retinal gene therapy[J]. JAMA Ophthalmol, 2017, 135(3): 234-241. DOI: 10.1001/jamaophthalmol.2016.5630.
11.	趙燕, 吳建華, 嚴立. 玻璃體腔注射雷珠單抗聯合光動力療法治療息肉狀脈絡膜血管病變的臨床觀察[J]. 臨床眼科雜志, 2018, 26(1): 1-4. DOI: 10.3969/j.issn.1006-8422.2018.01.001.Zhao Y, Wu JH, Yan L. Clinical observation on the treatment of polypoidal choroidal vasculopathy with intravitreal ranibizumab in-jection and photodynamic therapy[J]. J Clin Ophthalmol, 2018, 26(1): 1-4. DOI: 10.3969/j.issn.1006-8422.2018.01.001.
12.	龔培, 王情, 吳福進. 康柏西普治療息肉狀脈絡膜血管病變的療效及對患者血液流變學的影響[J]. 臨床合理用藥雜志, 2023, 16(2): 149-152. DOI: 10.15887/j.cnki.13-1389/r.2023.02.046.Gong P, Wang Q, Wu FJ. Efficacy of Conbercept in the treatment of polypoid choroidal vascular lesions and its effect on the hemorheology of patients[J]. Chin J of Clinical Rational Drug Use, 2023, 16(2): 149-152. DOI: 10.15887/j.cnki.13-1389/r.2023.02.046.
13.	劉炳乾, 盧百陽, 王雪, 等. 抗VEGF注射治療對息肉狀脈絡膜血管病變患者脈絡膜新生血管的抑制作用觀察[J]. 海軍醫學雜志, 2023, 44(4): 392-396. DOI: 10.3969/j.issn.1009-0754.Liu BQ, Lu BY, Wang X, et al. Observation on the inhibitory effects of anti-VEGF injection on choroidal neovascularization in the patients with polypoid choroidal vasculopathy[J]. Journal of Navy Medicine, 2023, 44(4): 392-396. DOI: 10.3969/j.issn.1009-0754.
14.	Tripepi D, Jalil A, Ally N, et al. The role of subretinal injection in ophthalmic surgery: therapeutic agent delivery and other indications[J/OL]. Int J Mol Sci, 2023, 24(13): 10535[2023-06-23]. https://pubmed.ncbi.nlm.nih.gov/37445711/. DOI: 10.3390/ijms241310535.
15.	Haupert CL, McCuen BN, Jaffe GJ, et al. Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration[J]. Am J Ophthalmol, 2001, 131(2): 208-215. DOI: 10.1016/s0002-9394(00)00734-0.
16.	Romano MR, Rossi T, Borgia A, et al. Management of refractory and recurrent macular holes: a comprehensive review[J]. Surv Ophthalmol, 2022, 67(4): 908-931. DOI: 10.1016/j.survophthal.2022.01.006.
17.	Malik D, Tarek M, Caceres del Carpio J, et al. Safety profiles of anti-VEGF drugs: Bevacizumab, Ranibizumab, Aflibercept and ziv-Aflibercept on human retinal pigment epithelium cells in culture[J]. Br J Ophthalmol, 2014, 98 Suppl 1: S11-16. DOI: 10.1136/bjophthalmol-2014-305302.
18.	Takahashi K, Morizane Y, Hisatomi T, et al. The influence of subretinal injection pressure on the microstructure of the monkey retina[J/OL]. PLoS One, 2018, 13(12): e209996[2018-12-31]. https://pubmed.ncbi.nlm.nih.gov/30596769/. DOI: 10.1371/journal.pone.0209996.
19.	Peng J, Liang T, Chen C, et al. Subretinal injection of ranibizumab in advanced pediatric vasoproliferative disorders with total retinal detachments[J]. Graefe's Arch Clin Exp Ophthalmol, 2020, 258(5): 1005-1012. DOI: 10.1007/s00417-020-04600-3.
20.	Yao TT, Yang Y, Jin XL, et al. Intraocular pharmacokinetics of anti-vascular endothelial growth factor agents by intraoperative subretinal versus intravitreal injection in silicone oil-filled eyes of proliferative diabetic retinopathy: a randomized controlled pilot study[J/OL]. Acta Ophthalmol, 2020, 98(7): e795-e800[2020-02-29]. https://pubmed.ncbi.nlm.nih.gov/32114709/. DOI: 10.1111/aos.14386.
21.	Inoue M, Arakawa A, Yamane S, et al. Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy[J]. Eye (Lond), 2013, 27(9): 1013-1021. DOI: 10.1038/eye.2013.179.
22.	Connor KM, Krah NM, Dennison RJ, et al. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis[J]. Nat Protoc, 2009, 4(11): 1565-1573. DOI: 10.1038/nprot.2009.187.
23.	曾苗, 陳曉, 洪玲, 等. 視網膜下注射平衡鹽溶液治療難治性糖尿病黃斑水腫的初步報告[J]. 中華眼底病雜志, 2020, 36(6): 462-466. DOI: 10.3760/cma.j.cn511434-20190304-00065.Zeng M, Chen X, Hong L, et al. Subretinal injection of balanced salt solution for the resolution of refractory diabetic macular edema[J]. Chin J Ocul Fundus Dis, 2020, 36(6): 462-466. DOI: 10.3760/cma.j.cn511434-20190304-00065.
24.	Ijuin N, Tsujinaka H, Hirai H, et al. Clinical implications of pachyvessels in polypoidal choroidal vasculopathy[J]. BMC Ophthalmol, 2020, 20(1): 170. DOI: 10.1186/s12886-020-01443-8.
25.	龔丹丹, 張福燕. 脈絡膜增厚型疾病的研究進展[J]. 中國社區醫師, 2020, 36(4): 6-7. DOI: 10.3969/j.issn.1007-614x.2020.04.002.Gong DD, Zhang FY. Research progress of choroidal thickening disease[J]. Chinese Community Doctors, 2020, 36(4): 6-7. DOI: 10.3969/j.issn.1007-614x.2020.04.002.
26.	董素, 蔣博, 張中宇, 等. 息肉狀脈絡膜血管病變中脈絡膜異常改變的研究進展[J]. 國際眼科縱覽, 2021, 45(2): 98-102. DOI: 10.3760/cma.j.issn.1673-5803.2021.02.003.Dong S, Jiang B, Zhong ZY, et al. Progress of choroidal abnormal changes in polypoid choroidal vasculopathy[J]. Int Rev Ophthalmol, 2021, 45(2): 98-102. DOI: 10.3760/cma.j.issn.1673-5803.2021.02.003.
27.	Jung JJ, Hoang QV, Arain MZY, et al. Aflibercept anti‐vascular endothelial growth factor therapy in vitrectomized eyes with neovascular age‐related macular degeneration[J/OL]. Acta Ophthalmologica, 2016, 94(3): e249-e250[2015-09-24]. https://pubmed.ncbi.nlm.nih.gov/26401896/. DOI: 10.1111/aos.12840.
28.	張香閨, 宋艷萍, 黃珍, 等. 康柏西普與雷珠單抗治療nARMD伴纖維血管性色素上皮脫離的效果比較[J]. 國際眼科雜志, 2022, 22(6): 1025-1031. DOI: 10.3980/j.issn.1672-5123.2022.6.28.Zhang XG, Song YP, Huang Z, et al. Comparison of the efficacy of Conbercept and Ranibizumab for nARMD with fibrovascular pigment epithelial detachment[J]. Int Eye Sci, 2022, 22(6): 1025-1031. DOI: 10.3980/j.issn.1672-5123.2022.6.28.
29.	宋華. 雷珠單抗治療滲出型AMD伴漿液性視網膜色素上皮脫離的效果分析[J]. 國際眼科雜志, 2017, 17(10): 1942-1944. DOI: 10.3980/j.issn.1672-5123.2017.10.37.Song H. Analysis of the therapeutic effect of Ranibizumab in the treatment of exudative AMD with serous PED in elderly patients[J]. Int Eye Sci, 2017, 17(10): 1942-1944. DOI: 10.3980/j.issn.1672-5123.2017.10.37.
30.	白玉婧, 黎曉新. 新生血管性老年性黃斑變性藥物治療面臨的挑戰與未來的發展趨勢[J]. 中華眼底病雜志, 2016, 32(1): 3-7. DOI: 10.3760/cma.j.issn.1005-1015.2016.01.002.Bai YJ, Li XX. Progression and challenge of therapeutic strategies in neovascular age-related macular degeneration[J]. Chin J Ocul Fundus Dis, 2016, 32(1): 3-7. DOI: 10.3760/cma.j.issn.1005-1015.2016.01.002.
31.	吳若欣, 徐潔慧, 溫積全, 等. 玻璃體內注射康柏西普對滲出性老年性黃斑變性患者脈絡膜厚度的影響[J]. 眼科新進展, 2016, 36(12): 1172-1175. DOI: 10.13389/j. cnki. rao. 2016.0312. 172-1175.Wu RX, Xu JH, Wen JQ, et al. Effects of intravitreal conbercept injections on choroidal thickness in exudative age-related macular degeneration[J]. Rec Adv Ophthalmol, 2016, 36(12): 1172-1175. DOI: 10.13389/j.cnki.rao.2016.0312.

1. Cher YX, Zhang YQ, Chen CZ, et al. Chinese guideline on the management of polypoidal choroidal vasculopathy (2022)[J]. Chin Med Sci J, 2023, 38(2): 77-93. DOI: 10.24920/004213.
2. Cheung C, Lai T, Teo K, et al. Polypoidal choroidal vasculopathy: consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup[J]. Ophthalmology, 2021, 128(3): 443-452. DOI: 10.1016/j.ophtha.2020.08.006.
3. 任晴, 崔蕾, 高磊. 息肉樣脈絡膜血管病變的臨床特征與手術治療進展[J]. 國際眼科雜志, 2018, 18(10): 1810-1814. DOI: 10.3980/j.issn.1672-5123.2018.10.12.Ren Q, Cui L, Gao L. Clinical features and progress of surgical therapy for polypoidal choroidal vasculopathy[J]. Int Eye Sci, 2018, 18(10): 1810-1814. DOI: 10.3980/j.issn.1672-5123.2018.10.12.
4. Chen LJ, Cheng CK, Yeung L, et al. Management of polypoidal choroidal vasculopathy: experts consensus in Taiwan[J]. J Formos Med Assoc, 2020, 119(2): 569-576. DOI: 10.1016/j.jfma.2019.04.012.
5. Sen P, Manayath G, Shroff D, et al. Polypoidal choroidal vasculopathy: an update on diagnosis and treatment[J]. Clin Ophthalmol, 2023, 17: 53-70. DOI: 10.2147/OPTH.S385827.
6. 朱哲. 影響息肉狀脈絡膜血管病變(PCV)患者發生黃斑區視網膜下纖維化瘢痕的相關因素分析[D]. 長春: 吉林大學, 2021.Zhu Z. Analysis of related factors affecting subretinal fibrosis scar in macular area in patients with polypoid choroidal vasculopathy (PCV)[D]. Changchun: Jilin University, 2021.
7. 梁燕華, 宋艷萍, 丁琴, 等. 單純光動力療法與玻璃體腔注射雷珠單抗以及兩者聯合治療息肉樣脈絡膜血管病變療效比較[J]. 中華眼底病雜志, 2016, 32(1): 31-35. DOI: 10.3760/cmaj. issn. 1005-1015.2016. 01.008.Liang YH, Song YP, Ding Q, et al. Efficacy of photodynamic therapy and intravitreal injection of ranibizumab in patients with polypoidal choroidal vasculopathy[J]. Chin J Ocul Fundus Dis, 2016, 32(1): 31-35. DOI: 10.3760/cmaj.issn.1005-1015.2016.01.008.
8. Irigoyen C, Amenabar Alonso A, Sanchez-Molina J, et al. Subretinal injection techniques for retinal disease: a review[J]. Journal of Clinical Medicine, 2022, 11(16): 4717. DOI: 10.3390/jcm11164717.
9. Del AE, Rimpela AK, Heikkinen E, et al. Pharmacokinetic aspects of retinal drug delivery[J]. Prog Retin Eye Res, 2017, 57: 134-185. DOI: 10.1016/j.preteyeres.2016.12.001.
10. Simunovic MP, Xue K, Jolly JK, et al. Structural and functional recovery following limited iatrogenic macular detachment for retinal gene therapy[J]. JAMA Ophthalmol, 2017, 135(3): 234-241. DOI: 10.1001/jamaophthalmol.2016.5630.
11. 趙燕, 吳建華, 嚴立. 玻璃體腔注射雷珠單抗聯合光動力療法治療息肉狀脈絡膜血管病變的臨床觀察[J]. 臨床眼科雜志, 2018, 26(1): 1-4. DOI: 10.3969/j.issn.1006-8422.2018.01.001.Zhao Y, Wu JH, Yan L. Clinical observation on the treatment of polypoidal choroidal vasculopathy with intravitreal ranibizumab in-jection and photodynamic therapy[J]. J Clin Ophthalmol, 2018, 26(1): 1-4. DOI: 10.3969/j.issn.1006-8422.2018.01.001.
12. 龔培, 王情, 吳福進. 康柏西普治療息肉狀脈絡膜血管病變的療效及對患者血液流變學的影響[J]. 臨床合理用藥雜志, 2023, 16(2): 149-152. DOI: 10.15887/j.cnki.13-1389/r.2023.02.046.Gong P, Wang Q, Wu FJ. Efficacy of Conbercept in the treatment of polypoid choroidal vascular lesions and its effect on the hemorheology of patients[J]. Chin J of Clinical Rational Drug Use, 2023, 16(2): 149-152. DOI: 10.15887/j.cnki.13-1389/r.2023.02.046.
13. 劉炳乾, 盧百陽, 王雪, 等. 抗VEGF注射治療對息肉狀脈絡膜血管病變患者脈絡膜新生血管的抑制作用觀察[J]. 海軍醫學雜志, 2023, 44(4): 392-396. DOI: 10.3969/j.issn.1009-0754.Liu BQ, Lu BY, Wang X, et al. Observation on the inhibitory effects of anti-VEGF injection on choroidal neovascularization in the patients with polypoid choroidal vasculopathy[J]. Journal of Navy Medicine, 2023, 44(4): 392-396. DOI: 10.3969/j.issn.1009-0754.
14. Tripepi D, Jalil A, Ally N, et al. The role of subretinal injection in ophthalmic surgery: therapeutic agent delivery and other indications[J/OL]. Int J Mol Sci, 2023, 24(13): 10535[2023-06-23]. https://pubmed.ncbi.nlm.nih.gov/37445711/. DOI: 10.3390/ijms241310535.
15. Haupert CL, McCuen BN, Jaffe GJ, et al. Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration[J]. Am J Ophthalmol, 2001, 131(2): 208-215. DOI: 10.1016/s0002-9394(00)00734-0.
16. Romano MR, Rossi T, Borgia A, et al. Management of refractory and recurrent macular holes: a comprehensive review[J]. Surv Ophthalmol, 2022, 67(4): 908-931. DOI: 10.1016/j.survophthal.2022.01.006.
17. Malik D, Tarek M, Caceres del Carpio J, et al. Safety profiles of anti-VEGF drugs: Bevacizumab, Ranibizumab, Aflibercept and ziv-Aflibercept on human retinal pigment epithelium cells in culture[J]. Br J Ophthalmol, 2014, 98 Suppl 1: S11-16. DOI: 10.1136/bjophthalmol-2014-305302.
18. Takahashi K, Morizane Y, Hisatomi T, et al. The influence of subretinal injection pressure on the microstructure of the monkey retina[J/OL]. PLoS One, 2018, 13(12): e209996[2018-12-31]. https://pubmed.ncbi.nlm.nih.gov/30596769/. DOI: 10.1371/journal.pone.0209996.
19. Peng J, Liang T, Chen C, et al. Subretinal injection of ranibizumab in advanced pediatric vasoproliferative disorders with total retinal detachments[J]. Graefe's Arch Clin Exp Ophthalmol, 2020, 258(5): 1005-1012. DOI: 10.1007/s00417-020-04600-3.
20. Yao TT, Yang Y, Jin XL, et al. Intraocular pharmacokinetics of anti-vascular endothelial growth factor agents by intraoperative subretinal versus intravitreal injection in silicone oil-filled eyes of proliferative diabetic retinopathy: a randomized controlled pilot study[J/OL]. Acta Ophthalmol, 2020, 98(7): e795-e800[2020-02-29]. https://pubmed.ncbi.nlm.nih.gov/32114709/. DOI: 10.1111/aos.14386.
21. Inoue M, Arakawa A, Yamane S, et al. Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy[J]. Eye (Lond), 2013, 27(9): 1013-1021. DOI: 10.1038/eye.2013.179.
22. Connor KM, Krah NM, Dennison RJ, et al. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis[J]. Nat Protoc, 2009, 4(11): 1565-1573. DOI: 10.1038/nprot.2009.187.
23. 曾苗, 陳曉, 洪玲, 等. 視網膜下注射平衡鹽溶液治療難治性糖尿病黃斑水腫的初步報告[J]. 中華眼底病雜志, 2020, 36(6): 462-466. DOI: 10.3760/cma.j.cn511434-20190304-00065.Zeng M, Chen X, Hong L, et al. Subretinal injection of balanced salt solution for the resolution of refractory diabetic macular edema[J]. Chin J Ocul Fundus Dis, 2020, 36(6): 462-466. DOI: 10.3760/cma.j.cn511434-20190304-00065.
24. Ijuin N, Tsujinaka H, Hirai H, et al. Clinical implications of pachyvessels in polypoidal choroidal vasculopathy[J]. BMC Ophthalmol, 2020, 20(1): 170. DOI: 10.1186/s12886-020-01443-8.
25. 龔丹丹, 張福燕. 脈絡膜增厚型疾病的研究進展[J]. 中國社區醫師, 2020, 36(4): 6-7. DOI: 10.3969/j.issn.1007-614x.2020.04.002.Gong DD, Zhang FY. Research progress of choroidal thickening disease[J]. Chinese Community Doctors, 2020, 36(4): 6-7. DOI: 10.3969/j.issn.1007-614x.2020.04.002.
26. 董素, 蔣博, 張中宇, 等. 息肉狀脈絡膜血管病變中脈絡膜異常改變的研究進展[J]. 國際眼科縱覽, 2021, 45(2): 98-102. DOI: 10.3760/cma.j.issn.1673-5803.2021.02.003.Dong S, Jiang B, Zhong ZY, et al. Progress of choroidal abnormal changes in polypoid choroidal vasculopathy[J]. Int Rev Ophthalmol, 2021, 45(2): 98-102. DOI: 10.3760/cma.j.issn.1673-5803.2021.02.003.
27. Jung JJ, Hoang QV, Arain MZY, et al. Aflibercept anti‐vascular endothelial growth factor therapy in vitrectomized eyes with neovascular age‐related macular degeneration[J/OL]. Acta Ophthalmologica, 2016, 94(3): e249-e250[2015-09-24]. https://pubmed.ncbi.nlm.nih.gov/26401896/. DOI: 10.1111/aos.12840.
28. 張香閨, 宋艷萍, 黃珍, 等. 康柏西普與雷珠單抗治療nARMD伴纖維血管性色素上皮脫離的效果比較[J]. 國際眼科雜志, 2022, 22(6): 1025-1031. DOI: 10.3980/j.issn.1672-5123.2022.6.28.Zhang XG, Song YP, Huang Z, et al. Comparison of the efficacy of Conbercept and Ranibizumab for nARMD with fibrovascular pigment epithelial detachment[J]. Int Eye Sci, 2022, 22(6): 1025-1031. DOI: 10.3980/j.issn.1672-5123.2022.6.28.
29. 宋華. 雷珠單抗治療滲出型AMD伴漿液性視網膜色素上皮脫離的效果分析[J]. 國際眼科雜志, 2017, 17(10): 1942-1944. DOI: 10.3980/j.issn.1672-5123.2017.10.37.Song H. Analysis of the therapeutic effect of Ranibizumab in the treatment of exudative AMD with serous PED in elderly patients[J]. Int Eye Sci, 2017, 17(10): 1942-1944. DOI: 10.3980/j.issn.1672-5123.2017.10.37.
30. 白玉婧, 黎曉新. 新生血管性老年性黃斑變性藥物治療面臨的挑戰與未來的發展趨勢[J]. 中華眼底病雜志, 2016, 32(1): 3-7. DOI: 10.3760/cma.j.issn.1005-1015.2016.01.002.Bai YJ, Li XX. Progression and challenge of therapeutic strategies in neovascular age-related macular degeneration[J]. Chin J Ocul Fundus Dis, 2016, 32(1): 3-7. DOI: 10.3760/cma.j.issn.1005-1015.2016.01.002.
31. 吳若欣, 徐潔慧, 溫積全, 等. 玻璃體內注射康柏西普對滲出性老年性黃斑變性患者脈絡膜厚度的影響[J]. 眼科新進展, 2016, 36(12): 1172-1175. DOI: 10.13389/j. cnki. rao. 2016.0312. 172-1175.Wu RX, Xu JH, Wen JQ, et al. Effects of intravitreal conbercept injections on choroidal thickness in exudative age-related macular degeneration[J]. Rec Adv Ophthalmol, 2016, 36(12): 1172-1175. DOI: 10.13389/j.cnki.rao.2016.0312.

Chinese Journal of Ocular Fundus Diseases

Analysis of the efficacy of subretinal injection and intravitreal injection of conbercept in the treatment of polypoidal choroidal vasculopathy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content